Page last updated: 2024-11-12

wrenchnolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

wrenchnolol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11228149
CHEMBL ID2170196
SCHEMBL ID14003415
MeSH IDM0466609

Synonyms (6)

Synonym
wrenchnolol
chembl2170196 ,
bdbm50396057
SCHEMBL14003415
rentinolol
4-[1-(adamantane-1-carbonyl)piperidin-4-yl]-n-(5-aminopentyl)-n-[2-hydroxy-3-[1-(4-methylphenyl)sulfonylindol-4-yl]oxypropyl]piperidine-1-carboxamide

Research Excerpts

Overview

Wrenchnolol is a cell-permeable synthetic organic molecule that mimics ELF3. It is relatively specific for binding to ELf3's coactivator, MED23.

ExcerptReferenceRelevance
"Wrenchnolol is a cell-permeable synthetic organic molecule that mimics ELF3 and is relatively specific for binding to ELF3's coactivator, MED23, as our data also showed in JEG3."( ELF3 activated by a superenhancer and an autoregulatory feedback loop is required for high-level HLA-C expression on extravillous trophoblasts.
Buenrostro, JD; Du, Z; Kshirsagar, S; Li, Q; Ma, S; Meissner, TB; Strominger, JL; Tilburgs, T; Uesugi, M; Wang, F, 2021
)
1.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mediator of RNA polymerase II transcription subunit 23Homo sapiens (human)Kd1.80001.80001.80001.8000AID700859
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
regulation of DNA-templated transcriptionMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
transcription initiation at RNA polymerase II promoterMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
RNA polymerase II preinitiation complex assemblyMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
positive regulation of transcription initiation by RNA polymerase IIMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
positive regulation of T cell extravasationMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
positive regulation of gene expressionMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
regulation of transcription by RNA polymerase IIMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
transcription coactivator activityMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
protein bindingMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleusMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
nucleoplasmMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
core mediator complexMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
transcription regulator complexMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
mediator complexMediator of RNA polymerase II transcription subunit 23Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID700859Binding affinity to Sur22011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
The many faces of the adamantyl group in drug design.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (71.43)29.6817
2010's1 (14.29)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (42.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]